

1 **Cross-sectional associations of dietary and circulating magnesium with skeletal muscle mass in**
2 **the EPIC-Norfolk cohort.**

3 Richard P G Hayhoe^a, Marleen A H Lentjes^b, Angela A Mulligan^b, Robert N Luben^b, Kay-Tee Khaw^b,
4 and Ailsa A Welch^a.

5 ^aDepartment of Population Health and Primary Care, Norwich Medical School, Faculty of Medicine
6 and Health Sciences, University of East Anglia, Norwich, NR4 7TJ. (RPGH, AAW)

7 ^bDepartment of Public Health and Primary Care, Institute of Public Health, University of Cambridge,
8 Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN. (MAHL, AAM, RNL,
9 K-TK)

10 *Corresponding Author:* Dr Ailsa A Welch, Department of Population Health and Primary Care,
11 Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia,
12 Norwich, NR4 7TJ. Email: a.welch@uea.ac.uk Tel: 01603 591950

13 *Requests for reprints:* as above for correspondence.

14 *Running head:* associations of dietary and circulating magnesium with skeletal muscle mass

15 *Names for PubMed indexing:* Hayhoe, Lentjes, Mulligan, Luben, Khaw, Welch.

16

17 *Abbreviations:* BIA (Bioelectrical impedance analyser); DINER (Data Into Nutrients for
18 Epidemiological Research); EAR (Estimated Average Requirement); EPIC (European Prospective
19 Investigation into Cancer and Nutrition); FFM (Fat Free Mass), FFM% (Percentage Fat Free Mass),
20 FFM_{BMI} (Fat Free Mass standardised by Body Mass Index), FFQ (Food-Frequency Questionnaire);
21 HLQ (Health and Lifestyle Questionnaire); HRT (Hormone Replacement Therapy); RNI (Reference
22 Nutrient Intake).

23 This paper should be read with the accompanying supplemental material.

24

25 **ABSTRACT**

26 **Background:** Maintenance of skeletal muscle in older age is critical to reducing frailty and the risk of
27 falls and fractures. Nutrition has established importance for muscle health in general, but less research
28 has looked at associations of dietary intake of specific micronutrients on skeletal muscle mass in older
29 adults.

30 **Aims:** This study aimed to investigate the influence of dietary and circulating magnesium on skeletal
31 muscle mass in a UK population of 14,340 middle to older-aged men and women participating in the
32 EPIC-Norfolk cohort study.

33 **Methods:** Dietary nutrient intakes were estimated from 7-day food diaries and fat-free mass (FFM) by
34 bioelectrical impedance analysis. Multivariable regression was used to investigate associations of
35 FFM-based indices of muscle mass with quintiles of dietary magnesium intake or serum magnesium
36 concentration groups. All analyses were stratified by sex, and regression models were adjusted for
37 relevant covariates.

38 **Results:** Significant positive trends in FFM measures were evident across magnesium dietary intake
39 quintiles for both sexes (all $p < 0.001$; $n = 6350$ men; $n = 7990$ women) and both < 60 and ≥ 60 year olds,
40 with all-age quintile 5 *versus* quintile 1 maximal differences of 4.6% in men and 6.3% in women;
41 highly relevant compared to the estimated 1% decline per year after 40 years of age. These
42 observations were not reflected in serum magnesium analyses, where no consistent trends were found
43 across the skeletal muscle mass indices tested.

44 **Conclusion:** Further investigation will be required to improve our understanding of the relationship
45 between serum magnesium concentration and skeletal muscle mass. However, this study has
46 demonstrated strong associations between dietary magnesium intake and indices of skeletal muscle
47 mass in a UK population of middle to older-aged adults, highlighting the likely importance of dietary
48 magnesium for optimal muscle health in this population.

49

50 **Keywords:** Sarcopenia, skeletal muscle, ageing, nutrition, general population studies.

51 **INTRODUCTION**

52 Sarcopenia is a syndrome characterised by a progressive and generalised loss of skeletal muscle mass
53 and function with age (1). Significant reduction in skeletal muscle mass and strength impairs static
54 and dynamic balance, which may increase risk of falls and thus the risk of resultant fractures (2).
55 Indirectly, the maintenance of skeletal muscle is important in protecting against osteoporosis since the
56 mechanical force of muscle contractions stimulates bone modelling and remodelling, which increases
57 bone strength and mass (3). Previous research has also shown skeletal muscle mass to be positively
58 correlated with both bone mineral content and density (2). Sarcopenia can therefore have significant
59 implications for affected individuals, placing them at risk of adverse outcomes including physical
60 frailty and falls, and resulting in an increased need for health and social care services (4). Muscle
61 tissue also has a metabolic role in the body and thus loss of muscle mass may result in other
62 detrimental outcomes, including change to metabolic rate, insulin resistance, and increased risk of
63 hypertension (5).

64
65 Sarcopenia is a complex condition, with many contributory factors including hormonal changes,
66 decreased protein synthesis, low-grade inflammation, oxidative stress, mitochondrial dysfunction, and
67 neuromuscular ageing. Nevertheless, interventions targeting modifiable lifestyle behaviours, such as
68 physical activity or diet, provide a potential strategy to reduce severity (4). It is recognised that
69 appropriate nutrition is critical for normal muscle metabolism, but influences of specific dietary
70 nutrients on sarcopenia are less well defined. Dietary protein has received most attention in the past
71 (6), but more recently the importance of other dietary components, including vitamin D (7) and
72 antioxidant micronutrients vitamins C (8) and E (9,10), has been suggested. Likewise, the mineral
73 magnesium has drawn some attention. Older individuals may be particularly susceptible to developing
74 low magnesium status due to physiological decline in function of the gastrointestinal and renal
75 systems causing a reduction in absorption of dietary magnesium and an increase in urinary excretion
76 (11). Second only to bone, skeletal muscle acts as a major store of magnesium where it is important

77 for energy metabolism, transmembrane transport, and muscle contraction and relaxation (12).
78 Magnesium supplementation has been shown to increase the muscle strength young adults gained
79 through exercise (13) and improve physical performance in older individuals (14). Epidemiological
80 studies have shown higher dietary magnesium intakes associated with greater skeletal muscle mass
81 and function (15) (16,17), and a significant positive association of serum magnesium concentration
82 with muscle performance in older adults (18). However, a comprehensive population cohort analysis
83 of dietary and circulating magnesium associations with skeletal muscle measures in both men and
84 women is currently lacking. This study therefore aims to address this by exploring the potential
85 associations of dietary magnesium intake and serum magnesium concentration with bio-impedance
86 estimated fat free mass (as a measure of skeletal muscle mass), in a mixed-sex UK population of
87 middle to older-aged individuals.

88

89 **MATERIALS AND METHODS**

90 Data analysed in this cross-sectional cohort study were from the Norfolk component of the European
91 Prospective Investigation into Cancer and Nutrition (EPIC). Written informed consent was provided
92 by participants according to the Declaration of Helsinki, and all procedures were approved by The
93 Norfolk District Health Authority Ethics Committee. Full details of recruitment to this cohort and the
94 procedures involved have been described previously (19). In summary, 25,639 men and women aged
95 40-79 years old living in the general community in Norfolk, UK, were recruited to the study and
96 participated in a baseline health-check between 1993 and 1997. Of these, 15,028 participants aged 42-
97 82 years had further data recorded at a second health-check between 1997 and 2000, when
98 bioelectrical impedance analysis (BIA) was undertaken.

99

100 At both health checks, height and weight were measured according to standard protocols (19). Height
101 was recorded to the nearest millimetre using a free-standing stadiometer and weight to the nearest 0.1
102 kilograms using calibrated digital scales with the participant wearing light clothing and no shoes. BMI

103 was calculated from these measurements (kg/m^2). BIA was carried out using a previously validated
104 (20,21) standard technique (Bodystat, Isle of Man, UK). The Tanita TBF-531 BIA analyser calculated
105 body density (BD) from total weight (Wt) in kg, height (Ht) in cm, and impedance (Z) in ohms, using
106 the following standard regression formulae for adults: BD in men = $1.100455 - 0.109766 \times \text{Wt} \times \text{Z} \div$
107 $\text{Ht}^2 + 0.000174 \times \text{Z}$; BD in women = $1.090343 - 0.108941 \times \text{Wt} \times \text{Z} \div \text{Ht}^2 + 0.00013 \times \text{Z}$. From this,
108 fat free mass (FFM) in kg was calculated: $\text{FFM} = \text{Wt} - ((4.57 \div \text{BD} - 4.142) \times \text{Wt})$. This estimates the
109 total mass of non-fat compartments of the body, i.e. metabolic tissue, intra- and extra-cellular water,
110 and bone tissue. As a further index for assessment, percentage FFM (FFM%) was calculated as FFM
111 divided by total weight multiplied by 100, and in order to scale for differences in skeletal muscle mass
112 with increasing body weight or stature, FFM standardised by BMI (FFM_{BMI}) was calculated as FFM
113 divided by BMI (22).

114

115 Health and lifestyle questionnaires, as previously described (19), were completed by all participants to
116 gather data including age, physical activity, social class, smoking status, menopausal status and HRT
117 use, and corticosteroid use. Each participant's physical activity status was categorised, according to a
118 heart-rate data validated method (19,23), as *inactive*, *moderately inactive*, *moderately active*, or *active*.

119 Dietary intakes were assessed using 7 day food diaries completed by each participant detailing all
120 food and drink consumed, together with the portion sizes (24). DINER (Data Into Nutrients for
121 Epidemiological Research) software was used to enter the dietary information provided by the diaries
122 (25), which was then checked and processed by nutritionists to obtain nutrient data, using DINERMO
123 (26). Serum magnesium concentration was determined using blood sampled by peripheral
124 venepuncture during the baseline health check. Samples were prepared, using a technique optimised
125 for use in EPIC, and stored in liquid nitrogen at -196°C until analysed by Quotient Bioresearch,
126 Fordham, UK, using an Olympus AU640 Chemistry Immuno Analyser to perform a xylydyl blue
127 based colorimetric assay (Beckman Coulter, USA). Measurements below 0.2 mmol/L or above 3.3
128 mmol/L were considered invalid and excluded from analyses.

130 The High Performance Computing Cluster supported by the Research and Specialist Computing
131 Support service at the University of East Anglia was used for statistical data analysis with STATA
132 software (v.13; Stata Corp., Texas). All analyses were stratified by sex since significant differences in
133 body composition and skeletal muscle mass exist between men and women. Any p values <0.05 were
134 considered to be statistically significant in individual analyses. Multivariable regression with
135 ANCOVA was used to investigate differences in skeletal muscle measures across sex-specific
136 quintiles of dietary magnesium intake. An adjusted model was tested, correcting for the potential
137 effects of physiological (age, menopausal status, HRT status, corticosteroid use, statin use), lifestyle
138 (smoking status, physical activity, social class) and dietary factors (total energy intake, and the
139 percentage of total energy from protein); also included was the energy intake to estimated energy
140 requirement ratio (EI:EER) as a percentage, to help correct for dietary misreporting (27). Likewise,
141 differences in skeletal muscle measures across sex-specific groups of serum magnesium concentration
142 were investigated using the same covariates, but excluding dietary factors in the adjusted model.
143 Serum magnesium concentration in healthy individuals is kept under tight homeostatic control;
144 published guidance suggests 0.7-1.0 mmol/L should be used as a reference range for healthy
145 individuals (28). Serum magnesium concentration groups were therefore categorised as <0.7 mmol/L
146 (group 1), 0.7-0.8 mmol/L (group 2), 0.8-0.9 mmol/L (group 3), 0.9-1.0 mmol/L (group 4), and >1.0
147 mmol/L (group 5). Group 2 has been used as the reference category for inter-group analyses.
148 Participants were excluded from analyses if they had missing or extreme (<300 or >1000 ohms (29))
149 BIA impedance values (n=228 and n=22), FFM < 25kg (n=13), BMI \geq 36 kg/m² (n=337), or had
150 missing values for any covariates included in the multivariable model (n=88 for diet analyses, and
151 n=48 for serum analyses). Analyses were repeated after stratifying for age (<60 and \geq 60 years).
152 Correlation between dietary and serum continuous scale magnesium variables was assessed by
153 Pearson correlation coefficient.

155 **RESULTS**

156 Selected characteristics of participants are summarised in **Table 1** stratified by sex. All variables were
157 significantly different in men and women except for corticosteroid and statin use. The UK Reference
158 Nutrient Intake (RNI) for magnesium is 300 mg per day for men over the age of 18 years and 270 mg
159 per day for women, while the Estimated Average Requirements (EARs) for men and women are 250
160 mg and 200 mg (30). In this cohort, mean dietary magnesium intakes were 332 ± 90 mg for men and
161 275 ± 73 mg for women. The largest contribution of magnesium in the diet of both men and women in
162 this cohort came from cereals and cereal foods (33.7% of total dietary magnesium in men; 32.4% in
163 women). Fruits and vegetables accounted for a further 11.5% in men and 15.0% in women, while hot
164 beverages provided 10.1% in men and 11.4% in women. Further detail of the contribution of foods to
165 magnesium intake is provided in **Supplemental Figure 1**. Prevalence of inadequate intakes estimated
166 using the EAR cut-point method (31) was 14.3%, with a greater number of men with inadequate
167 intakes than women (16.1% vs. 12.9%; $p < 0.001$; $n = 14340$). No correlation was evident between
168 magnesium dietary intake and serum concentration (Pearson's $r = 0.007$, $p = 0.646$, $n = 4611$ men; $r =$
169 0.030 , $p = 0.020$, $n = 5972$ women).

170
171 In dietary model analyses, there were significant positive trends across magnesium intake quintiles in
172 adjusted FFM, FFM%, and FFM_{BMI} for both men and women (all $p < 0.001$; $n = 6350$ men; $n = 7990$
173 women) (see **Supplemental Table 1**). These trends were evident in both < 60 ($n = 2366$ men; $n = 3535$
174 women) and ≥ 60 year olds ($n = 3984$ men; $n = 4455$ women) (see **Figure 1**). The largest all-age inter-
175 quintile differences were apparent in women where adjusted FFM for those in quintile 5 was 2.9%
176 greater than in quintile 1, FFM% was 4.2% greater, and FFM_{BMI} was 6.3% greater (all $p < 0.001$;
177 $n = 3196$); quintile 5 vs. 1 differences in men were 2.0% for FFM, 2.4% for FFM%, and 4.6% for
178 FFM_{BMI} (all $p < 0.001$; $n = 2540$). For women under 60 years of age, adjusted FFM in quintile 5 was
179 3.4% greater than in quintile 1, FFM% was 4.6% greater, and FFM_{BMI} was 7.2% greater (all $p < 0.001$;
180 $n = 1394$); in men the differences were 2.2% for FFM, 2.2% for FFM%, and 4.8% for FFM_{BMI} (all

181 $p < 0.001$; $n = 940$). For women 60 years or over, adjusted FFM in quintile 5 was 2.8% greater than in
182 quintile 1, FFM% was 4.6% greater, and FFM_{BMI} was 6.8% greater (all $p < 0.001$; $n = 1802$); in men the
183 differences were 1.8% for FFM, 2.8% for FFM%, and 5.0% for FFM_{BMI} (all $p < 0.001$; $n = 1600$).

184

185 In all-age serum model analyses (see **Supplemental Table 2**) no linear trends were apparent between
186 magnesium serum concentration groups and FFM, FFM%, or FFM_{BMI}; likewise, no significant
187 differences were identified between muscle mass measures in the low normal concentration group
188 (group 2) *vs.* other groups. However, stratifying the serum data by age highlighted some significant
189 differences (see **Figure 2**). In individuals ≥ 60 years old, FFM was significantly lower in magnesium
190 concentration group 4 *vs.* group 2 in both men ($p = 0.031$; $n = 1131$) and women ($p = 0.020$; $n = 1311$), and
191 group 5 *vs.* group 2 in women only ($p = 0.029$; $n = 928$).

192

193 **DISCUSSION**

194 This study, using data from a large population cohort, has shown that associations between dietary
195 magnesium and indices of skeletal muscle mass exist in both men and women. Significant positive
196 trends in FFM, FFM% and FFM_{BMI} were evident across increasing quintiles of dietary magnesium
197 intake for both sexes, which remained after adjustment for important biological, lifestyle and other
198 dietary covariates. These results corroborate previous smaller-scale studies including the positive
199 relationship between magnesium intake and dual-energy X-ray absorptiometry-assessed appendicular
200 lean mass in individuals aged 50 to 79 years in the Tasmanian Older Adult Cohort Study (15), the
201 greater FFM seen with higher intakes of dietary magnesium in a UK study of women aged 34 to 83
202 years from the TwinsUK cohort (16), and the more recent large-scale cross-sectional analysis of
203 FFM% and FFM_{BMI} using UK Biobank data (17). Associations between serum magnesium
204 concentration groups and skeletal muscle mass indices are less clear, although this is unsurprising
205 considering the tight homeostatic control of circulating magnesium and the fact that less than 1% of
206 total body magnesium is present in the blood (32). This homeostatic control makes it less likely that a

207 serum magnesium concentration outside the normal range represents an extreme dietary intake of
208 magnesium, and more likely that it is the result of a pathological problem (e.g. abnormal renal
209 wasting) or diuretic medication (32). Indeed, our results showed correlation of magnesium serum
210 concentration with dietary intake in the EPIC-Norfolk cohort was negligible. Previous studies have
211 demonstrated that despite presenting with normal serum magnesium concentration, some individuals
212 may be severely magnesium deficient, with low concentrations in bone and muscle due to long-term
213 compensatory release of magnesium to maintain serum concentration when dietary intake has been
214 low for a long period of time (33). This may partly explain the inconsistent associations between
215 serum magnesium concentrations and skeletal muscle mass indices apparent in this study.

216
217 It is important to appreciate the magnitude of the differences seen with the dietary analyses. Indeed,
218 considering that the effect of age on skeletal muscle mass is already well-established (34), and
219 confirmed in this dataset where FFM_{BMI} was 5.4% lower in those ≥ 60 years *versus* those < 60 years
220 (data not shown), the differences seen according to magnesium intake are highly relevant. For
221 example, the difference in adjusted FFM_{BMI} between magnesium quintile 5 and quintile 1 for women
222 was 6.3%. Furthermore, the difference in median daily dietary intake between quintiles 1 and 5 for
223 women was 173 mg, a difference which should be achievable as part of a normal diet (for example, by
224 $\frac{1}{2}$ cup boiled spinach, $\frac{1}{4}$ cup roasted peanuts, and a medium-sized banana (35)). However, since a
225 typical Western diet containing a high proportion of processed foods and limited whole grains and
226 green vegetables is often deficient in magnesium (36), more needs to be done to promote an adequate
227 diet and avoid adverse musculoskeletal consequences.

228
229 Although sarcopenia is a particular issue in individuals aged 60 years old or older, loss of skeletal
230 muscle mass has been documented to progress from the age of 30 years onwards (4). Age
231 stratification of our dietary magnesium analyses demonstrated largely similar effects for those less
232 than 60 years of age, and those 60 years or older, albeit with lower values for muscle mass indices in

233 the older age group. This highlights the potential benefits of dietary magnesium for musculoskeletal
234 health in all ages of this cohort, and raises the possibility that optimal dietary magnesium intake could
235 help preserve skeletal muscle before sarcopenia becomes problematic later in life.

236

237 While previous research has demonstrated magnesium status to be strongly correlated with muscle
238 performance in both young and old individuals (13,14), the mechanisms by which magnesium may
239 influence muscle are not yet fully understood. Magnesium is critical for basic mitochondrial function:
240 cell-culture and animal studies have demonstrated that magnesium depletion can cause structural
241 damage to muscle cells due to oxidative stress and disrupted calcium homeostasis (37). In addition,
242 magnesium also has a postulated role in protecting against the chronic low-grade inflammation
243 associated with ageing and a known risk factor for sarcopenia (4). Indeed, circulating concentrations
244 of inflammatory cytokines, including C-reactive protein (CRP), IL-6, and TNF- α , have been
245 negatively associated with skeletal muscle measures of both mass and function in a number of studies
246 (16,38-40), and systematic review evidence indicates that dietary magnesium intake is inversely
247 associated with serum CRP concentration (41).

248

249 It is interesting to consider how results for the alternative skeletal muscle indices translate into clinical
250 importance for sarcopenia. FFM_{BMI} may provide a more useful measure than unstandardised FFM or
251 FFM% to assess change in skeletal muscle mass while correcting for differences attributable to body
252 size. This index has recently been used to define cutpoints in the Foundation for the National Institutes
253 of Health Biomarkers Consortium Sarcopenia Project (42), and as it is used in more studies of
254 different populations we will gain a greater understanding of how it describes body composition in
255 both normal and sarcopenic individuals.

256

257 This is the first study to have investigated associations between both dietary intake and circulating
258 magnesium, and measures of skeletal muscle in a mixed-sex UK cohort of older adults. However, we

259 recognise there are a number of limitations. These include the observational and cross-sectional study
260 design which precludes us from attributing causal links between magnesium dietary intake or serum
261 concentration and skeletal muscle measures, and reliance on self-reported measures for diet and
262 physical activity data. Nevertheless, the quantitative 7-day food diaries developed for use in EPIC
263 have been validated previously and are expected to provide more precise dietary intake figures
264 compared to alternative FFQ or 24-hour recall methods (26). Magnesium dietary data analysed here
265 were derived from food intake only, and therefore may underestimate total nutrient intakes. However,
266 the supplements consumed by this cohort provide a relatively small contribution to total magnesium
267 intake and thus are likely to have a negligible effect on our results (43). We assessed magnesium
268 status using serum magnesium concentrations which may not be the most reliable marker of Mg status
269 as discussed earlier. However, the preferred alternative of timed 24 hour urine collection which
270 linearly reflects dietary intake may be even less reliable for older individuals due to problems with
271 urine collection and complications of diuretic use (11). Magnetic resonance measurement of ionised
272 magnesium within skeletal muscle could provide useful data (44), but this method was not practical
273 for our large population sample, and thus serum magnesium measurement remains a useful indicator
274 of magnesium status for this type of study (45). Indices of skeletal muscle mass were calculated from
275 weight, height, and bioelectrical-impedance measurements, rather than the potentially more accurate
276 and precise methods of dual-energy X-ray absorptiometry, computer tomography, or magnetic
277 resonance imaging (46). However, bio-electrical impedance assessment has the advantage of avoiding
278 accessibility issues, costs, and radiation, associated with other methods. Consequences of loss of
279 skeletal muscle mass may extend beyond a reduction in strength and function due to the metabolic
280 role of muscle, and may include changes to metabolic rate, insulin resistance, and increased risk of
281 hypertension (5). While in this study it has not been possible to analyse functional muscle measures in
282 relation to magnesium we believe it is important to have considered the fundamental body
283 composition information provided by BIA data.

284

285 **Conclusions**

286 This study has highlighted strong positive associations between dietary magnesium intake and indices
287 of skeletal muscle mass in both men and women of the EPIC-Norfolk cohort, with the scale of effects
288 highly relevant in comparison to age-related losses. The results for circulating magnesium are less
289 patent, potentially due to the tight homeostatic control of blood magnesium concentrations. These
290 findings, which being observational in nature require confirmation by clinical trial, support a
291 hypothesis that dietary magnesium is beneficial to skeletal muscle health in older individuals.

292
293 **Acknowledgements**

294 We thank all the EPIC-Norfolk study participants and coordination staff.

295 The authors' contributions to the manuscript were: AAW developed the research question together
296 with RPGH who performed the data analyses and drafted the manuscript. AAW organised data
297 collection in conjunction with RNL who implemented the record linkage. MAHL and AAM prepared
298 dietary and supplemental data for statistical analysis. K-TK is principal investigator of the EPIC-
299 Norfolk Study. All authors were involved in interpreting the data, contributed to the writing of the
300 manuscript, and read and approved the final manuscript. None of the authors had a financial or
301 personal conflict of interest relevant to this research at the time of writing.

302
303 **Funding**

304 The EPIC-Norfolk study was supported by funding from the Medical Research Council (G9502233)
305 and Cancer Research UK (SP2024-0201 and SP2024-0204).

306
307 **REFERENCES**

- 308
309 1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and
310 diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age
311 Ageing. 2010;39(4):412-23.

- 312 2. Szulc P, Beck TJ, Marchand F, Delmas PD. Low skeletal muscle mass is associated with poor
313 structural parameters of bone and impaired balance in elderly men--the MINOS study. *J Bone*
314 *Miner Res.* 2005;20(5):721-9.
- 315 3. Russo CR. The effects of exercise on bone. Basic concepts and implications for the prevention of
316 fractures. *Clin Cases Miner Bone Metab.* 2009;6(3):223-8.
- 317 4. Welch AA. Nutritional influences on age-related skeletal muscle loss. *Proc Nutr Soc.*
318 2014;73(1):16-33.
- 319 5. Karakelides H, Nair KS. Sarcopenia of aging and its metabolic impact. *Curr Top Dev Biol.*
320 2005;68:123-48.
- 321 6. Paddon-Jones D, Short KR, Campbell WW, Volpi E, Wolfe RR. Role of dietary protein in the
322 sarcopenia of aging. *Am J Clin Nutr.* 2008;87(5):1562S-6S.
- 323 7. Arik G, Ulger Z. Vitamin D in sarcopenia: Understanding its role in pathogenesis, prevention and
324 treatment. *Eur Geriatr Med.* 2016;7(3):207-13.
- 325 8. Cesari M, Pahor M, Bartali B, et al. Antioxidants and physical performance in elderly persons: the
326 *Invecchiare in Chianti (InCHIANTI)* study. *Am J Clin Nutr.* 2004;79(2):289-94.
- 327 9. Khor SC, Abdul Karim N, Ngah WZ, Yusof YA, Makpol S. Vitamin E in sarcopenia: current
328 evidences on its role in prevention and treatment. *Oxid Med Cell Longev.* 2014;2014:914853.
- 329 10. Mulligan AA, Lentjes MAH, Luben RN, Khaw KT, Welch AA. Dietary vitamin E intake is
330 associated with greater fat-free mass and percentage fat-free mass in the EPIC-Norfolk cohort.
331 *Proceedings of the Nutrition Society.* 2016;75(OCE3).
- 332 11. Veronese N, Zanchini BM, Manzato E, Sergi G. Magnesium and healthy aging. *Magnesium*
333 *research : official organ of the International Society for the Development of Research on*
334 *Magnesium.* 2015;28(3):112-5.
- 335 12. Jahnen-Dechent W, Ketteler M. Magnesium basics. *Clin Kidney J.* 2012;5(Suppl 1):i3-i14.
- 336 13. Brilla LR, Haley TF. Effect of magnesium supplementation on strength training in humans. *J Am*
337 *Coll Nutr.* 1992;11(3):326-9.

- 338 14. Veronese N, Berton L, Carraro S, et al. Effect of oral magnesium supplementation on physical
339 performance in healthy elderly women involved in a weekly exercise program: a randomized
340 controlled trial. *Am J Clin Nutr.* 2014;100(3):974-81.
- 341 15. Scott D, Blizzard L, Fell J, Giles G, Jones G. Associations between dietary nutrient intake and
342 muscle mass and strength in community-dwelling older adults: the Tasmanian Older Adult
343 Cohort Study. *Journal of the American Geriatrics Society.* 2010;58(11):2129-34.
- 344 16. Welch AA, Kelaiditi E, Jennings A, Steves CJ, Spector TD, MacGregor A. Dietary Magnesium Is
345 Positively Associated With Skeletal Muscle Power and Indices of Muscle Mass and May
346 Attenuate the Association Between Circulating C-Reactive Protein and Muscle Mass in
347 Women. *J Bone Miner Res.* 2016;31(2):317-25.
- 348 17. Welch AA, Skinner J, Hickson M. Dietary Magnesium May Be Protective for Aging of Bone and
349 Skeletal Muscle in Middle and Younger Older Age Men and Women: Cross-Sectional
350 Findings from the UK Biobank Cohort. *Nutrients.* 2017;9(11).
- 351 18. Dominguez LJ, Barbagallo M, Lauretani F, et al. Magnesium and muscle performance in older
352 persons: the InCHIANTI study. *Am J Clin Nutr.* 2006;84(2):419-26.
- 353 19. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort.
354 European Prospective Investigation of Cancer. *Br J Cancer.* 1999;80 Suppl 1:95-103.
- 355 20. Shanholtzer BA, Patterson SM. Use of bioelectrical impedance in hydration status assessment:
356 reliability of a new tool in psychophysiology research. *Int J Psychophysiol.* 2003;49(3):217-
357 26.
- 358 21. Simpson JA, Lobo DN, Anderson JA, et al. Body water compartment measurements: a
359 comparison of bioelectrical impedance analysis with tritium and sodium bromide dilution
360 techniques. *Clin Nutr.* 2001;20(4):339-43.
- 361 22. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study
362 description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci.*
363 2014;69(5):547-58.

- 364 23. Wareham NJ, Jakes RW, Rennie KL, et al. Validity and repeatability of a simple index derived
365 from the short physical activity questionnaire used in the European Prospective Investigation
366 into Cancer and Nutrition (EPIC) study. *Public Health Nutr.* 2003;6(4):407-13.
- 367 24. Bingham SA, Welch AA, McTaggart A, et al. Nutritional methods in the European Prospective
368 Investigation of Cancer in Norfolk. *Public Health Nutr.* 2001;4(3):847-58.
- 369 25. Welch AA, McTaggart A, Mulligan AA, et al. DINER (Data Into Nutrients for Epidemiological
370 Research) - a new data-entry program for nutritional analysis in the EPIC-Norfolk cohort and
371 the 7-day diary method. *Public Health Nutr.* 2001;4(6):1253-65.
- 372 26. Lentjes MA, McTaggart A, Mulligan AA, et al. Dietary intake measurement using 7 d diet diaries
373 in British men and women in the European Prospective Investigation into Cancer-Norfolk
374 study: a focus on methodological issues. *Br J Nutr.* 2013:1-11.
- 375 27. Murakami K, Livingstone MB. Prevalence and characteristics of misreporting of energy intake in
376 US adults: NHANES 2003-2012. *Br J Nutr.* 2015;114(8):1294-303.
- 377 28. Ayuk J, Gittoes NJ. Contemporary view of the clinical relevance of magnesium homeostasis.
378 *Annals of clinical biochemistry.* 2014;51(Pt 2):179-88.
- 379 29. Fish RM, Geddes LA. Medical and bioengineering aspects of electrical injuries. Tucson: Lawyers
380 & Judges; 2003.
- 381 30. Department of Health. Dietary Reference Values for Food Energy and Nutrients for the United
382 Kingdom. Report on Health and Social Subjects No 41. London: HSMO; 1991.
- 383 31. Sobiecki JG, Appleby PN, Bradbury KE, Key TJ. High compliance with dietary recommendations
384 in a cohort of meat eaters, fish eaters, vegetarians, and vegans: results from the European
385 Prospective Investigation into Cancer and Nutrition-Oxford study. *Nutr Res.* 2016;36(5):464-
386 77.
- 387 32. Wu J, Carter A. Magnesium: the forgotten electrolyte. *Aust Prescr.* 2007;30:102-5.
- 388 33. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease.
389 *Physiol Rev.* 2015;95(1):1-46.

- 390 34. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle
391 mass in elderly men and women. *Mech Ageing Dev.* 1999;107(2):123-36.
- 392 35. National Institutes of Health Office of Dietary Supplements. Magnesium Fact Sheet for Health
393 Professionals. 2016.
- 394 36. Rayssiguier Y, Mazur A, Durlach J. *Advances in magnesium research : nutrition and health.*
395 Eastleigh: John Libbey; 2001.
- 396 37. Rock E, Astier C, Lab C, et al. Dietary magnesium deficiency in rats enhances free radical
397 production in skeletal muscle. *J Nutr.* 1995;125(5):1205-10.
- 398 38. Aleman H, Esparza J, Ramirez FA, Astiazaran H, Payette H. Longitudinal evidence on the
399 association between interleukin-6 and C-reactive protein with the loss of total appendicular
400 skeletal muscle in free-living older men and women. *Age Ageing.* 2011;40(4):469-75.
- 401 39. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons:
402 associations with 5-year change in muscle mass and muscle strength. *J Gerontol A Biol Sci*
403 *Med Sci.* 2009;64(11):1183-9.
- 404 40. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older
405 persons: the InCHIANTI study. *J Gerontol A Biol Sci Med Sci.* 2004;59(3):242-8.
- 406 41. Dibaba DT, Xun P, He K. Dietary magnesium intake is inversely associated with serum C-reactive
407 protein levels: meta-analysis and systematic review. *Eur J Clin Nutr.* 2014;68(4):510-6.
- 408 42. Cawthon PM, Peters KW, Shardell MD, et al. Cutpoints for low appendicular lean mass that
409 identify older adults with clinically significant weakness. *J Gerontol A Biol Sci Med Sci.*
410 2014;69(5):567-75.
- 411 43. Lentjes MA, Bhaniani A, Mulligan AA, Khaw KT, Welch AA. Developing a database of vitamin
412 and mineral supplements (ViMiS) for the Norfolk arm of the European Prospective
413 Investigation into Cancer (EPIC-Norfolk). *Public Health Nutr.* 2011;14(3):459-71.

- 414 44. Ryschon TW, Rosenstein DL, Rubinow DR, Niemela JE, Elin RJ, Balaban RS. Relationship
415 between skeletal muscle intracellular ionized magnesium and measurements of blood
416 magnesium. *J Lab Clin Med.* 1996;127(2):207-13.
- 417 45. Rosanoff A, Dai Q, Shapses SA. Essential Nutrient Interactions: Does Low or Suboptimal
418 Magnesium Status Interact with Vitamin D and/or Calcium Status? *Advances in nutrition.*
419 2016;7(1):25-43.
- 420 46. Cooper C, Fielding R, Visser M, et al. Tools in the assessment of sarcopenia. *Calcified tissue*
421 *international.* 2013;93(3):201-10.
- 422

425 **Table 1** – Selected characteristics of the EPIC-Norfolk cohort population stratified by sex for the diet
 426 analysis group (n=14,340) and the serum analysis group (n=10,611).

Selected Characteristics	Diet analysis group			Serum analysis group		
	Men	Women	<i>P</i> ¹	Men	Women	<i>P</i>
	n=6350	n=7990		n=4628	n=5983	
Age (years)	62.9 ± 9.0 ²	61.5 ± 9.0	<0.001	62.9 ± 8.7 ²	61.6 ± 8.9	<0.001
BMI (kg/m ²)	26.7 ± 3.0	26.1 ± 3.7	<0.001	26.7 ± 3.0	26.0 ± 3.7	<0.001
Magnesium intake (mg/day)	332 ± 90	275 ± 73	<0.001	--	--	
Total energy intake (kcal/day)	2286 ± 500	1735 ± 378	<0.001	--	--	
Protein % of energy	14.8 ± 2.4	15.5 ± 2.8	<0.001	--	--	
Serum [Mg] (mmol/L)	--	--		0.82 ± 0.11	0.80 ± 0.12	<0.001
FFM (kg)	61.6 ± 5.9	40.6 ± 4.5	<0.001	61.7 ± 5.9	40.6 ± 4.5	<0.001
FFM%	76.7 ± 5.8	60.9 ± 8.3	<0.001	76.8 ± 5.8	61.1 ± 8.1	<0.001
FFM _{BMI}	2.33 ± 0.26	1.58 ± 0.26	<0.001	2.33 ± 0.26	1.59 ± 0.26	<0.001
EI/EER%	91.1 ± 20.7	93.7 ± 21.8	<0.001	--	--	
Smoking			<0.001			<0.001
Current	542 (8.5)	696 (8.7)		375 (8.1)	489 (8.2)	
Former	3524 (55.5)	2551 (31.9)		2552 (55.1)	1909 (31.9)	
Never	2284 (36.0)	4743 (59.4)		1701 (36.8)	3585 (59.9)	
Physical activity			<0.001			<0.001
Inactive	1736 (27.3)	2070 (25.9)		1236 (26.7)	1537 (25.7)	
Moderately inactive	1595 (25.1)	2600 (32.5)		1164 (25.2)	1927 (32.2)	
Moderately active	1590 (25.0)	1933 (24.2)		1160 (25.1)	1445 (24.2)	
Active	1429 (22.5)	1387 (17.4)		1068 (23.1)	1074 (18.0)	
Corticosteroid use			0.391			0.391
Never (<3 months)	6086 (95.8)	7583 (94.9)		4444 (96.0)	5698 (95.2)	
Current or former (>3 months)	264 (4.2)	407 (5.1)		184 (4.0)	285 (4.8)	
Statin use			0.391			0.391
No	6003 (94.5)	7700 (96.4)		4389 (94.8)	5769 (96.4)	
Yes	347 (5.5)	290 (3.6)		239 (5.2)	214 (3.6)	
Menopausal status						
Pre-menopausal	--	475 (5.9)		--	475 (5.9)	
Peri-menopausal (<1 y)	--	266 (3.3)		--	266 (3.3)	
Peri-menopausal (1-5 y)	--	1400 (17.5)		--	1400 (17.5)	
Post-menopausal	--	5849 (73.2)		--	5849 (73.2)	
HRT						
Current	--	1704 (21.3)		--	1704 (21.3)	

Former	--	1432 (17.9)	--	1432 (17.9)
Never	--	4854 (60.8)	--	4854 (60.8)
Social Class			<i><0.001</i>	<i><0.001</i>
Professional	523 (8.2)	547 (6.8)	385 (8.3)	401 (6.7)
Managerial	2587 (40.7)	2950 (36.9)	1917 (41.4)	2226 (37.2)
Skilled non-manual	797 (12.6)	1554 (19.4)	567 (12.3)	1180 (19.7)
Skilled manual	1422 (22.4)	1577 (19.7)	1055 (22.8)	1190 (19.9)
Semi-skilled	781 (12.3)	950 (11.9)	537 (11.6)	688 (11.5)
Non-skilled	149 (2.3)	267 (3.3)	99 (2.1)	197 (3.3)
Un-coded	91 (1.4)	145 (1.8)	68 (1.5)	101 (1.7)

428 ¹P values are for differences between men and women, according to t-test for continuous or chi-square

429 for categorical variables. ²Values are mean ± SD or frequency (percentage).

430 **Figure 1** – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by
431 sex, age group, and quintiles of dietary magnesium intake (n=14,340).

432

433 * p<0.05; ** p<0.01; *** p<0.001 *versus* quintile 1, according to ANCOVA.

434 Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status,
435 physical activity, social class, total energy intake, percentage of total energy from protein, and
436 EI:EER.

437 Values are presented as mean ± SE.

438 **Mg intake (mean ± SD; mg/day) by Mg quintiles (Q).** *Men ≤60 years:* Mean, 350 ± 92; Q1, 226 ±
439 30; Q2, 283 ± 12; Q3, 323 ± 11; Q4, 368 ± 15; Q5, 470 ± 73. *Men >60 years:* Mean, 322 ± 87; Q1,
440 223 ± 31; Q2, 282 ± 12; Q3, 322 ± 11; Q4, 366 ± 16; Q5, 465 ± 71. *Women ≤60 years:* Mean, 285 ±
441 75; Q1, 187 ± 27; Q2, 235 ± 10; Q3, 268 ± 10; Q4, 305 ± 12; Q5, 385 ± 62. *Women >60 years:* Mean,
442 268 ± 71; Q1, 186 ± 26; Q2, 234 ± 10; Q3, 267 ± 10; Q4, 304 ± 13; Q5, 381 ± 56.

443

444

445 **Figure 2** – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by
446 sex, age group, and serum concentration groups (n=10,611).

447

448 * p<0.05; ** p<0.01; *** p<0.001 *versus* group 2, according to ANCOVA.

449 Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status,
450 physical activity, and social class.

451 Values are presented as mean ± SE.

452 **Serum Mg concentration groups:** <0.7 mmol/L (group 1), 0.7-0.8 mmol/L (group 2), 0.8-0.9
453 mmol/L (group 3), 0.9-1.0 mmol/L (group 4), and >1.0 mmol/L (group 5).

Figure 1










Figure 2




Serum Mg Group

Serum Mg Group

■ < 60 years
■ ≥ 60 years

Supplemental Figure 1 – Percentage contribution of different foods to the dietary magnesium intake of EPIC-Norfolk cohort participants, stratified by sex (n=25,507).



Rice and pasta 1.8% men, 2.0% women; bread and crackers 17.2% men, 16.3% women; breakfast cereals 9.0% men, 9.0% women; cakes, biscuits, and desserts 3.8% men, 3.5% women; cereals (not breakfast) 1.9% men, 1.7 women; milk 7.5% men, 8.0 women; cheese 1.4% men, 1.3% women; dairy

(not milk or cheese) 2.7% men, 3.7 women; eggs 0.7% men, 0.6% women; potatoes 8.5% men, 7.7% women; vegetables and pulses 6.3% men, 6.9% women; fruit 5.3% men, 8.1% women; nuts 1.6% men 1.5% women; fish 3.3% men, 3.4% women; meat 7.7% men, 7.1% women; hot beverages 10.1% men, 11.4% women; soft drinks 0.2% men, 0.2% women; juice 1.1% men 1.5% women; beer 4.4% men, 0.5% women; alcoholic drinks (not beer) 2.0% men, 2.0 women; soups and sauces 1.4% men, 1.5 women; snacks 2.1% men, 2.2% women; miscellaneous 0.2% men, 0.2% women.

Supplemental Table 1 – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by sex and quintiles of dietary magnesium intake (n=14,340).

	Dietary magnesium intake												P trend
	Total		Quintile 1		Quintile 2		Quintile 3		Quintile 4		Quintile 5		
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE	
Men	n=6350		n=1270		n=1270		n=1270		n=1270		n=1270		
FFM (kg)	61.64	0.04	60.88	0.11	61.52***	0.10	61.82***	0.09	61.90***	0.10	62.10***	0.11	<0.001
FFM%	76.72	0.06	75.94	0.14	76.36*	0.13	76.56**	0.12	76.92***	0.13	77.80***	0.14	<0.001
FFM _{BMI}	2.33	0.003	2.27	0.008	2.31***	0.007	2.32***	0.007	2.34***	0.007	2.38***	0.008	<0.001
Women	n=7990		n=1598		n=1598		n=1598		n=1598		n=1598		
FFM (kg)	40.61	0.04	40.01	0.11	40.45***	0.09	40.64***	0.09	40.78***	0.10	41.19***	0.11	<0.001
FFM%	60.91	0.07	59.90	0.19	60.46*	0.16	60.58**	0.16	61.15***	0.16	62.45***	0.18	<0.001
FFM _{BMI}	1.58	0.003	1.54	0.007	1.57***	0.006	1.57***	0.006	1.59***	0.006	1.64***	0.007	<0.001

* p<0.05; ** p<0.01; *** p<0.001 versus quintile 1.

Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status, physical activity, social class, total energy intake, percentage of total energy from protein, and EI:EER.

Mg intake (mean ± SD; mg/day) by Mg quintiles (Q). Men: Mean, 332 ± 90; Q1, 224 ± 31; Q2, 282 ± 12; Q3, 322 ± 11; Q4, 367 ± 16; Q5, 467 ± 72. Women: Mean, 275 ± 73; Q1, 186 ± 25; Q2, 235 ± 10; Q3, 268 ± 10; Q4, 304 ± 13; Q5, 383 ± 73.

Supplemental Table 2 – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by sex and serum concentration groups (n=10,611).

	Serum magnesium concentration group											
	Total		Group 1		Group 2		Group 3		Group 4		Group 5	
	<i>Mean</i>	<i>SE</i>	<i>Mean</i>	<i>SE</i>	<i>Mean</i>	<i>SE</i>	<i>Mean</i>	<i>SE</i>	<i>Mean</i>	<i>SE</i>	<i>Mean</i>	<i>SE</i>
Men	n=4628		n=480		n=1128		n=2242		n=710		n=68	
FFM (kg)	61.67	0.09	61.43	0.26	61.64	0.17	61.84	0.12	61.27	0.22	61.52	0.70
FFM%	76.76	0.08	77.18	0.26	76.83	0.17	76.61	0.12	76.89	0.21	76.17	0.69
FFM _{BMI}	2.33	0.004	2.33	0.011	2.33	0.007	2.33	0.005	2.32	0.009	2.34	0.030
Women	n=5983		n=845		n=1694		n=2721		n=661		n=62	
FFM (kg)	40.64	0.06	40.62	0.15	40.77	0.11	40.62	0.09	40.38	0.17	40.32	0.57
FFM%	61.09	0.10	60.99	0.28	61.04	0.20	61.17	0.15	61.05	0.31	60.42	1.02
FFM _{BMI}	1.59	0.003	1.58	0.009	1.59	0.006	1.59	0.005	1.59	0.010	1.58	0.032

Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status, physical activity, and social class.

Serum Mg concentration groups: <0.7 mmol/L (group 1), 0.7-0.8 mmol/L (group 2), 0.8-0.9 mmol/L (group 3), 0.9-1.0 mmol/L (group 4), and >1.0 mmol/L (group 5).